{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:04Z","timestamp":1790916964911,"version":"4.1.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The devastating pandemic of coronavirus disease 2019 (COVID-19) highlighted the importance of early detection and global collaboration in combating infectious diseases. Namibia is one of the countries that bears a high burden of tuberculosis (TB) and human immunodeficiency virus (HIV) infection. The overlap of these diseases underscores the need to better understand host immune responses, which play a critical role in disease pathogenesis and may differ across infections. This study aimed to profile selected cytokines and chemokines among Namibian individuals with TB, latent TB infection (LTBI), COVID-19, and HIV infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A cross-sectional study was conducted between August 2022 and May 2023 among adults (\u226518 years) recruited from two clinics in Namibia. 222 participants were categorized into multiple clinical groups, including mono- and co-infections of COVID-19, active TB, LTBI, HIV, and control participants. Serum concentrations of 23 cytokines and chemokines were measured using the LEGENDPlex\u2122 multiplex immunoassay. Differences, discriminations and correlations in biomarker levels between groups were analysed using non-parametric statistical tests with adjustment for multiple comparisons. Statistical significance was defined as an adjusted\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u00a00.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MCP-1 demonstrated consistent upregulation across active TB, COVID-19, COVID-19\/LTBI, and HIV\/LTBI groups. In contrast, free active transforming growth factor beta 1 (TGF-\u03b21) was significantly downregulated in both TB and LTBI participants. Individuals with TB exhibited elevated MCP-1 and macrophage migration inhibitory factor (MIF) levels compared to those with LTBI, with both analytes demonstrating discriminatory performance between TB and LTBI. Multiple moderate and weak positive correlations among inflammatory markers were observed in individuals with LTBI and HIV\/LTBI but were absent in active TB and COVID-19\/LTBI participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings demonstrate distinct serum cytokines and chemokines across TB, LTBI, HIV, and COVID-19 in a Namibian cohort. MCP-1 emerged as a consistent marker associated with inflammation. MIF was detected as a potential differentiating marker for TB and LTBI. Larger studies are needed to evaluate the diagnostic potential of these biomarkers and their incorporation into clinical diagnostic algorithms. The results also suggest a possible role for LTBI-associated immune activation in HIV co-infection, which warrants further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1954262","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:41:14Z","timestamp":1790916074000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative serum cytokine and chemokine profiles across tuberculosis, latent TB, HIV, and COVID-19 infections in Namibian adults"],"prefix":"10.3389","volume":"17","author":[{"given":"Ottilie K. H.","family":"Katali","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Microbiology and Biotechnology, University of Namibia","place":["Windhoek, Namibia"]},{"name":"Department of Human, Biological & Translational Medical Sciences, University of Namibia","place":["Windhoek, Namibia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hertz","sequence":"additional","affiliation":[{"name":"Host Determinants in Lung Infections, Research Center Borstel, Leibniz Lung Center","place":["Borstel, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareli","family":"Claassens","sequence":"additional","affiliation":[{"name":"Department of Human, Biological & Translational Medical Sciences, University of Namibia","place":["Windhoek, Namibia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrina","family":"Kapewangolo","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Microbiology and Biotechnology, University of Namibia","place":["Windhoek, Namibia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadesse K.","family":"Woldetsadik","sequence":"additional","affiliation":[{"name":"Health Poverty Action","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chawangwa","family":"Modongo","sequence":"additional","affiliation":[{"name":"Victus Global Botswana Organisation","place":["Gaborone, Botswana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Niemann","sequence":"additional","affiliation":[{"name":"Department of Human, Biological & Translational Medical Sciences, University of Namibia","place":["Windhoek, Namibia"]},{"name":"Molecular and Experimental Mycobacteriology, Research Center Borstel, Leibniz Lung Center","place":["Borstel, Germany"]},{"name":"German Center for Infection Research (DZIF), Partner Site Hamburg-L\u00fcbeck-Borstel-Riems","place":["Borstel, Germany"]},{"name":"Phylogenomics, Phylodynamics and Host-Pathogen Interactions team, EPHE, PSL University","place":["Paris, France"]},{"name":"Institut de Syst\u00e9matique, Evolution, Biodiversit\u00e9 (ISYEB), MNHN, CNRS, SU, UA, EPHE","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca E.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Host Determinants in Lung Infections, Research Center Borstel, Leibniz Lung Center","place":["Borstel, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Nepolo","sequence":"additional","affiliation":[{"name":"Department of Human, Biological & Translational Medical Sciences, University of Namibia","place":["Windhoek, Namibia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","unstructured":"Unaids Epidemiological Estimates\n          \n          2025"},{"key":"B2","volume-title":"Global Tuberculosis Report 2025","year":"2025"},{"key":"B3","unstructured":"Tuberculosis\n          \n          2025"},{"key":"B4","unstructured":"World Health Statistics 2025\n          \n          2025"},{"key":"B5","unstructured":"Coronavirus Disease (COVID-19)\n          \n          2025"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20499361211016973","article-title":"The impact of COVID-19 on tuberculosis: challenges and opportunities","volume":"8","author":"Kant","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijtb.2020.07.003","article-title":"COVID-19 -Tuberculosis interactions: When dark forces collide","volume":"67","author":"Udwadia","year":"2020","journal-title":"Indian J Tuberc"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1104828","article-title":"The COVID-19, tuberculosis and HIV\/AIDS: M\u00e9nage \u00e0 Trois","volume":"14","author":"Udoakang","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.09.011","article-title":"Pro- and anti-inflammatory cytokines in tuberculosis: A two-edged sword in TB pathogenesis","volume":"26","author":"Etna","year":"2014","journal-title":"Semin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155785","article-title":"Effect of SARS-CoV-2 seropositivity on antigen \u2013 specific cytokine and chemokine responses in latent tuberculosis","volume":"150","author":"Rajamanickam","year":"2022","journal-title":"Cytokine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/infdis\/jiae365","article-title":"Plasma immune biomarkers predictive of progression to active tuberculosis in household contacts of patients with tuberculosis","volume":"231","author":"Rajamanickam","year":"2025","journal-title":"J Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s10020-020-00230-x","article-title":"IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19","volume":"26","author":"Chen","year":"2020","journal-title":"Mol Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1186\/s12879-020-05450-4","article-title":"Implications of COVID-19 in high burden countries for HIV\/TB: A systematic review of evidence","volume":"20","author":"Tamuzi","year":"2020","journal-title":"BMC Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2019.0032","article-title":"Role of the innate cytokine storm induced by the influenza A virus","volume":"32","author":"Gu","year":"2019","journal-title":"Viral Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12985-022-01814-1","article-title":"COVID-19 infection: an overview on cytokine storm and related interventions","volume":"19","author":"Montazersaheb","year":"2022","journal-title":"Virol J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0640-2","article-title":"Cytokine storms in infectious diseases","volume":"39","author":"Teijaro","year":"2017","journal-title":"Semin Immunopathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-022-01870-3","article-title":"Plasma cytokine levels characterize disease pathogenesis and treatment response in tuberculosis patients","volume":"51","author":"Vivekanandan","year":"2023","journal-title":"Infection"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2021.104799","article-title":"The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong","volume":"153","author":"Darif","year":"2021","journal-title":"Microb Pathog"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 cytokine storm; what we know so far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.07.029","article-title":"Latent tuberculosis co-infection is associated with heightened levels of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection","volume":"83","author":"Rajamanickam","year":"2021","journal-title":"J Infect"},{"key":"B22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12916-020-01529-6","article-title":"Association between the cytokine storm, immune cell dynamics, and viral replicative capacity in hyperacute HIV infection","volume":"18","author":"Muema","year":"2020","journal-title":"BMC Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/srep36234","article-title":"Cytokine cascade and networks among MSM HIV seroconverters: implications for early immunotherapy","volume":"6","author":"Huang","year":"2016","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283367836","article-title":"Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression","volume":"24","author":"Roberts","year":"2010","journal-title":"AIDS"},{"key":"B25","unstructured":"Impact of puberty on immune responses to mycobacterium tuberculosis in south African adolescents\n          \n          \n            \n              Kleynhans\n              L\n            \n            \n              Maasdorp\n              E\n            \n            \n              Snyders\n              CI\n            \n            \n              Seddon\n              JA\n            \n          \n          \n          2025"},{"key":"B26","doi-asserted-by":"publisher","first-page":"8074183","DOI":"10.1155\/2020\/8074183","article-title":"Gaps in study design for immune parameter research for latent tuberculosis infection: A systematic review","volume":"2020","author":"Herrera","year":"2020","journal-title":"J Immunol Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20236008","article-title":"Cytokines in inflammatory disease","volume":"20","author":"Kany","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa363","article-title":"Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China","volume":"222","author":"Chi","year":"2020","journal-title":"J Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41392-020-0211-1","article-title":"Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients","volume":"5","author":"Xu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155389","article-title":"Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients","volume":"138","author":"B\u00fclow Anderberg","year":"2021","journal-title":"Cytokine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e14462","DOI":"10.1111\/ijcp.14462","article-title":"Changes of serum IL\u201010, IL\u20101\u03b2, IL\u20106, MCP\u20101, TNF\u2010\u03b1, IP\u201010 and IL\u20104 in COVID\u201019 patients","volume":"75","author":"Lu","year":"2021","journal-title":"Int J Clin Pract"},{"key":"B32","first-page":"107598","article-title":"MCP-1: Function, regulation, and involvement in disease","volume-title":"Int Immunopharmacol","author":"Singh","year":"2021"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytogfr.2012.10.002","article-title":"Chemokines shape the immune responses to tuberculosis","volume-title":"Cytokine and Growth Factor Reviews","author":"Slight","year":"2013"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2018.10.017","article-title":"Diagnostic performance of plasma cytokine biosignature combination and MCP-1 as individual biomarkers for differentiating stages Mycobacterium tuberculosis infection","volume":"78","author":"Luo","year":"2019","journal-title":"J Infect"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1600712l","article-title":"Performance of eight serum cytokine\/chemokine biomarkers in discriminating between active and latent tuberculosis infection in Ghana","volume":"16","author":"Mensah","year":"2025","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003523","article-title":"Latent tuberculosis is associated with heightened levels of pro-and anti-inflammatory cytokines among Kenyan men and women living with HIV on long-term antiretroviral therapy","volume":"37","author":"Temu","year":"2023","journal-title":"AIDS"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.908144","article-title":"Elevated IP-10 at the protein and gene level associates with pulmonary TB","volume":"12","author":"Fisher","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.12.019","article-title":"IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy","volume":"70","author":"Wergeland","year":"2015","journal-title":"J Infect"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2012.07.013","article-title":"Efficacy of inducible protein 10 as a biomarker for the diagnosis of tuberculosis","volume":"16","author":"Hong","year":"2012","journal-title":"Int J Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3343\/alm.2018.38.1.9","article-title":"Serum macrophage migration inhibitory factor as a biomarker of active pulmonary tuberculosis","volume":"38","author":"Shang","year":"2018","journal-title":"Ann Lab Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12931-019-1004-3","article-title":"Prognostic value of serum macrophage migration inhibitory factor levels in pulmonary tuberculosis","volume":"20","author":"Wang","year":"2019","journal-title":"Respir Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27189","article-title":"Evaluation of the relationship between macrophage migration inhibitory factor level and clinical course in patients with COVID\u201019 pneumonia","volume":"93","author":"Aksakal","year":"2021","journal-title":"J Med Virol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e133714","DOI":"10.5812\/archcid-133714","article-title":"Increasing levels of macrophage migration inhibitory factor in COVID-19 infection and its pathophysiological role; cut-off value determination might be clinically misleading","volume":"18","author":"Farzad","year":"2023","journal-title":"Arch Clin Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11020332","article-title":"Macrophage migration inhibitory factor (MIF) plasma concentration in critically ill COVID-19 patients: A prospective observational study","volume":"11","author":"Bleilevens","year":"2021","journal-title":"Diagnostics"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-023-04674-7","article-title":"Transforming growth factor beta 1 (TGF-\u03b21) in COVID-19 patients: relation to platelets and association with the disease outcome","volume":"478","author":"Zivancevic-Simonovic","year":"2023","journal-title":"Mol Cell Biochem"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202350433","article-title":"Serum TGF\u2010\u03b2 as a predictive biomarker for severe disease and fatality of COVID\u201019","volume":"53","author":"Frischbutter","year":"2023","journal-title":"Eur J Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29686","article-title":"Monocytes and macrophages: Origin, homing, differentiation, and functionality during inflammation","volume":"10","author":"Dash","year":"2024","journal-title":"Heliyon"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.70269","article-title":"Emerging insights into CC and CXC chemokines and their receptors in Mycobacterium tuberculosis infection","volume":"16","author":"Yin","year":"2026","journal-title":"FEBS Open Bio"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcsw.2025.100150","article-title":"Innate immune recognition of Mycobacterium tuberculosis: receptor engagement and inflammatory outcomes at the site of infection","volume":"14","author":"Mvubu","year":"2025","journal-title":"Cell Surf"},{"key":"B50","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12879-020-05047-x","article-title":"Serum level of IL-1ra was associated with the treatment of latent tuberculosis infection in a Chinese population","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Infect Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.8.6.1097-1103.2001","article-title":"Comparison of serum and cell-specific cytokines in humans","volume":"8","author":"Jason","year":"2001","journal-title":"Clin Diagn Lab Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1954262\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:41:26Z","timestamp":1790916086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1954262\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2026.1954262"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1954262","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1954262"}}